GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

XBIO · Mar 31, 2025

Xenetic Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001683168-25-003496General Corporate
Operating cash generation71thOwn-history percentile · N=17
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-168.88% · OPTIONAL · VALID

Revenue growth31thOwn-history percentile · N=13
Evidence method

Yoy · gp.fundamentals.revenue

16.14% · CORE · VALID

Operating margin88thOwn-history percentile · N=17
Evidence method

Level · gp.fundamentals.operating_margin

-158.85% · CORE · VALID

R&D intensity41thOwn-history percentile · N=17
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

148.17% · OPTIONAL · VALID

SBC intensity0thOwn-history percentile · N=17
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

3.24% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History19 statesSelf-history eligible
Period transition

What moved in the state?

Cash Generation Decreased
Previous
-112.69%
Current
-168.88%
Delta
-56.19%
Growth Increased
Previous
-1.56%
Current
16.14%
Delta
17.70%
Profitability Increased
Previous
-168.16%
Current
-158.85%
Delta
9.31%
R And D Intensity Increased
Previous
131.52%
Current
148.17%
Delta
16.65%
Sbc Intensity Decreased
Previous
6.87%
Current
3.24%
Delta
-3.63%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.